RNA antagonists - A new class of antisense drugs

IEEE Engineering in Medicine and Biology Magazine

Volumn 24, Issue 4, 2005, Pages 81-87

  Ørum, Henrik ^a  

^a Santaris Pharma AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; DOXORUBICIN; GEMCITABINE; LOCKED NUCLEIC ACID; MESSENGER RNA; PACLITAXEL; PROTEIN BCL 2; RNA ANATAGONIST; SMALL INTERFERING RNA; SPC 2968; SPC 2996; SPC 3042; SURVIVIN; THIOREDOXIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; COMPLEMENTARY RNA;

BINDING AFFINITY; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; HALF LIFE TIME; HUMAN; NONHUMAN; REVIEW; SENSITIVITY AND SPECIFICITY; ANIMAL; CLINICAL TRIAL; DRUG DESIGN; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; METHODOLOGY; PHARMACOGENETICS; RNA INTERFERENCE;

ANIMALS; CLINICAL TRIALS; DRUG DESIGN; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HUMANS; PHARMACOGENETICS; RNA INTERFERENCE; RNA, ANTISENSE;

EID: 23044451238     PISSN: 07395175     EISSN: None     Source Type: Journal    
DOI: 10.1109/MEMB.2005.1463401     Document Type: Review

References (32)

1. S.K. Singh, P. Nielsen, A.A. Koshkin, and J. Wengel, "LNA (locked nucleic acids): Synthesis and high-affinity nucleic acid recognition," Chem. Commun., pp. 455-456, 1998.
2. S. Obika, D. Nanbu, Y. Hari, J. Andoh, K. Mono, T. Doi, and T. Imanishi, "Stability and structural features of the duplexes containing nucleoside analogs with a fixed N-type conformation," 2′-O,4′-C- methyleneribonucleosides. Tetrahedron Lett., vol. 39, pp. 5401-5404, 1998.
3. J.S. Jepsen, M.D. Sørensen, and J. Wengel, "Locked nucleic acid: A potent nucleic acid analog in therapeutics and biotechnology," Oligonucleotides, vol. 14, pp. 130-146, 2004.
4. H. Ørum and J. Wengel, "Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development," Curr. Opin. Mol. Ther., vol. 3, pp. 239-243, 2001.
5. J. Elmén, H. Thonberg, K. Ljungberg, M. Frieden, M. Westergaard, Y. Xu, B. Wahren, Z. Liang, H. Ørum, T. Koch, and C. Wahlestedt, "Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality," Nucleic Acids Res., vol. 33, no. 1, pp. 439-447, 2005.
6. V. Hornung, M. Guenther-Biller, et al. "Sequence-specific potent induction of IFN/a by short interfering RNA in plasmacytoid dendritic cells through TLR7," Nature Medicine, vol. 11, no. 3, pp. 263-270, 2005.
7. D.A. Braasch, S. Jensen, Y. Liu, K. Kaur, K. Arar, M.A. White, and D.R. Corey, "RNA interference in mammalian cells by chemically-modified RNA," Biochem., vol. 42, pp. 7967-7975, 2003.
8. J. Wengel, M. Petersen, M. Frieden, and T. Kock, "Chemistry of locked nucleic acids (LNA): Design, synthesis, and bio-physical properties," Lett. Peptide Sci., vol. 10, pp. 237-253, 2003.
9. J. Wengel, A. Koshkin, S. K. Singh, P. Nielsen, M. Meldgaard, V.K. Rajwanshi, R. Kumar, J. Skouv, C.B. Nielsen, N. Jakobsen, and C.E. Olsen, "Locked nucleic acids (LNA)," Nucleosides Nucleotides, vol. 18, pp. 1365-1370, 1999.
10. A.N. Elayadi, D.A. Braasch, and D.R. Corey, "Implications of high-affinity hybridisation by locked nucleic acid oligomers for inhibition of human telomerase," Biochem., vol. 41, pp. 9973-9981, 2002.
11. A. Grüneweller, E. Wyszko, B. Bieber, R. Jahnel, V.A. Erdmann, and J. Kurreck, "Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA," Nucleic Acids Res., vol. 31, pp. 3185-3193, 2003.
12. A. Simöes-Wüst, S. Hopkins-Donaldson, B. Sigrist, L. Belyanskaya, R.A. Stahel, and U. Zangemeister-Wittke, "A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis," Oligonucleotides, vol. 14 pp. 199-209, 2004.
13. K. Fluiter, A.L.M.A. Ten Asbroek, M.B. De Wissel, M.E. Jakobs, M. Wissenbach, H. Olsson, O. Olsen, H. Oerum, and F. Baas, "In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides," Nucleic Acids Res., vol. 31 pp. 953-962 2003.
14. C. Wahlestedt, P. Salmi, L. Good, J. Kela, T. Johnsson, T. Hokfelt, C. Broberger, F. Porreca, J. Lai, K. Ren, M. Ossipov, A. Koshkin, N. Jakobsen, J. Skouv, H. Oerum, M.H. Jacobsen, and Wengel, "Potent and nontoxic antisense oligonucleotides containing locked nucleic acids," J. Proc. Nat. Acad. Sci. U.S.A., vol. 97, pp. 5633-5638, 2000.
15. A. Arzumanov, A.P. Walsh, V.K. Rajwanshi, RE. Kumar, J. Wengel, and M.J. Gait, "Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides," Biochem., vol. 40, pp. 14645-14654, 2001.
16. D. Braasch, Y. Liu, and D.R. Corey, "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: Effect of mRNA target sequence and chimera design," Nucleic Acids Res., vol. 30, pp. 5160-5167, 2002.
17. J. Soutschek, A. Aakinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavine, R.K. Pandey, T. Racie, K.G. Rajeev, I. Roehl, I. Toudjarska, G. Wang, S. Wuschko, D. Bumcrot, V. Koteliansky, S. Limmer, M. Manoharan, and H. Vornlocher, "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," Nature, vol. 432, pp. 173-178, 2004.
18. T. Charlier, G.F. Ball, and J. Balthazart, "Inhibition of steroid receptor coactivator-1 blocks estrogen and androgen action on male sex behavior and associated brain plasticity," J. Neurosci., vol. 25 pp. 906-913, 2005.
19. J. Kurreck, E. Wyszko, C. Gillen, and V.A. Erdmann, "Design of antisense oligonucleotides stabilized by locked nucleic acids," Nucleic Acids Res., vol. 30, pp. 1911-1918, 2002.
20. R.S. Geary, R.Z. Yu, J.M. Leeds, T.A. Watanabe, S.P. Henry, A.A. Levin, and M.V. Templin, "Pharmacokinetic properties in animals," in Antisense Drug Technology, Principles, Strategies, and Applications, S.T. Crooke, Ed. New York: Marcel Dekker, pp. 119-154.
21. R.M. Crooke and M.J. Graham, "Suborgan pharmakokinetics," in Antisense Drug Technology, Principles, Strategies, and Applications. S.T. Crooke, Ed. New York: Marcel Dekker, pp. 155-182.
22. M. Frieden, S.M. Christensen, N.D. Mikkelsen, C. Rosenbohm, C.A. Thrue, M. Westergaard, H.F. Hansen, H. Oerum, and T. Koch, Nucleic Acids Res., vol. 31, pp. 6365-6372, 2003.
23. A. Arzumanov, D.A. Stetsenko, A.D. Malakhov, S. Reichelt, M.D. Sørensen, R. Babu, J. Wengel, and M.J. Gait, "A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2′-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), □-L-LNA, or 2′-thio-LNA residues," Oligonucleotides, vol. 13, pp. 435-453, 2003.
24. K. Fluiter, M. Frieden, J. Vreijling, C. Rosenbohm, M.B. De Wissel, S.M. Christensen, T. Koch, H. Ørum, and F. Baas, "On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti H-Ras antisense oligonucleotide," Chem. Bio. Chem., vol. 6, pp. 1-7, 2005.
25. S.D. Paul, D. Rhodes, and D.J. Burgess, "DNA-based therapeutics and DNA delivery systems: A comprehensive review," AAPS J., vol. 7, pp. E61-E77, 2005.
26. G.E. Hardee, S.P. Weinbach, and L.G. Tillman, "New routes and novel formulations for delivery of antisense oligonucleotides," in Antisense Drug Technology, Principles, Strategies, and Applications. S.T. Crooke, Ed. New York: Marcel Dekker, pp. 795-832.
27. O. Khatsenko, R. Morgan, L. Truong, C. York-Defalco, H. Sasmor, B. Conklin, and R.S. Geray, "Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length," Antisense Nucleic Acid Drug Dev., vol. 10, pp. 35-44, 2000.
28. J. Vollmer, J.S. Jepsen, E. Uhlmann, C. Schetter, M. Jurk, T. Wader, M. Wullner, and A.M. Krieg, "Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA)," Oligonucleotides, vol. 14, pp. 23-31, 2004.
29. A.A. Levin, S.P. Henry, D. Moteith, and M.V. Templin, "Toxicity of antisense oligonucleotides," in Antisense Drug Technology, Principles, Strategies, and Applications, S.T. Crooke, Ed. New York: Marcel Dekker, pp. 201-267.
30. P.L. Iversen, K.G. Cornish, L.J. Iversen, J.E. Mata, and D.B. Bylund, "Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as α-adrenergic receptor antagonists," Toxicol. Appl. Pharmacol., vol. 160, pp. 289-296, 1999.
31. R.S. Geary, T.A. Watanabe, L. Truong, S. Freier, E.A. Lesnik, N.B. Sioufi, H. Sasmor, M. Manoharan, and A.A. Levin, "Pharmacokinetic properties of 2′-O-(2-methoxyethyl) modified oligonucleotide analogs in rats," J. Pharmacol. Experimental Therapeutics, vol. 296, pp. 890-897, 2001.
32. R.S. Geary, R.Z. Yu, T.A. Watanabe, S.P. Henry, G.E. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, and A.A. Levin, "Pharmacokinetics of a tumor necrosis factor-α phophorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: Comparison across species," Drug Metabolism Disposition, vol. 31, pp. 1419-1428, 2003.